Tumor Site- and Stage-Specific Associations between Allelic Variants of Glutathione S-Transferase and DNA-Repair Genes and Overall Survival in Colorectal Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy
Introduction Our retrospective cohort study investigated the effect of tumor site and stage on the associations between the allelic variants of glutathione S-transferase (GST) and DNA-repair genes and overall survival (OS) in CRC patients treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy. Material and Methods We genotyped GSTM1, GSTT1, GSTP1 Ile105Val, XRCC1 Arg399Gln, XRCC3 Thr241Met, and XPD Lys751Gln in 491 CRC patients between 1995 and 2001. A Cox proportional-hazards model was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the relationships between the allelic variants and OS. Survival analyses were performed for each allelic variant by using the log-rank test and Kaplan-Meier analysis. Results The CRC patients with the XPD Gln allelic variants had poorer survival than patients with the Lys/Lys genotype (HR = 1.38, 95% CI = 1.02–1.87), and rectal cancer patients had the poorest survival among them (HR = 1.87, 95% CI = 1.18–2.95). A significantly shorter OS was observed among stage II/III colon cancer patients with the XRCC1 Gln allelic variants (HR = 1.69, 95% CI = 1.06–2.71), compared to those with XRCC1 Arg/Arg genotype. In the combined analysis of the XRCC1 and XPD genes patients with stage II/III tumors, the poorest OS occurred in colon cancer patients with the XRCC1 Gln and XPD Gln allelic variants (HR = 2.60, 95% CI = 1.19–5.71) and rectal cancer patients with the XRCC1 Arg/Arg and XPD Gln allelic variants (HR = 2.77, 95% CI = 1.25–6.17). Conclusion The XPD and XRCC1 allelic variants may be prognostic markers for CRC patients receiving 5-FU based chemotherapy. The contributions of the XPD and XRCC1 allelic variants to OS are tumor site- and/or stage-dependent.
References
[1]
Moore HC, Haller DG (1999) Adjuvant therapy of colon cancer. Semin Oncol 26: 545–555.
[2]
Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, et al. (2008) Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19: 915–919.
[3]
Stewart JM, Zalcberg JR (1998) Update on adjuvant treatment of colorectal cancer. Curr Opin Oncol 10: 367–374.
[4]
Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA (1999) Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 8: 77–81.
[5]
Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, et al. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551–555.
[6]
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, et al. (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654–8658.
[7]
Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, et al. (2011) DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol 18: 2688–2698.
[8]
Liu L, Wu J, Zhong R, Wu C, Zou L, et al.. (2012) Multi-loci analysis reveals the importance of genetic variations in sensitivity of platinum-based chemotherapy in non-small-cell lung cancer. Mol Carcinog.
[9]
Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275–280.
[10]
Meyer DJ, Coles B, Pemble SE, Gilmore KS, Fraser GM, et al. (1991) Theta, a new class of glutathione transferases purified from rat and man. Biochem J 274 (Pt 2): 409–414.
[11]
Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, et al. (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936–942.
[12]
Ruzzo A, Canestrari E, Maltese P, Pizzagalli F, Graziano F, et al. (2007) Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin Chem Lab Med 45: 822–828.
[13]
Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y (2012) Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol 12: 137.
[14]
Chen YC, Tzeng CH, Chen PM, Lin JK, Lin TC, et al. (2010) Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101: 530–535.
[15]
Romero A, Martin M, Oliva B, de la Torre J, Furio V, et al. (2012) Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol 23: 1750–1756.
[16]
Shuck SC, Short EA, Turchi JJ (2008) Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 18: 64–72.
[17]
Rouillon C, White MF (2011) The evolution and mechanisms of nucleotide excision repair proteins. Res Microbiol 162: 19–26.
[18]
Melis JP, Luijten M, Mullenders LH, van Steeg H (2011) The role of XPC: implications in cancer and oxidative DNA damage. Mutat Res 728: 107–117.
[19]
Chen S, Tang D, Xue K, Xu L, Ma G, et al. (2002) DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 23: 1321–1325.
[20]
Mahimkar MB, Samant TA, Kannan S, Tulsulkar J, Pai PS, et al. (2012) Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog 51 Suppl 1E94–103.
[21]
Hitomi K, Iwai S, Tainer JA (2007) The intricate structural chemistry of base excision repair machinery: implications for DNA damage recognition, removal, and repair. DNA Repair (Amst) 6: 410–428.
[22]
Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, et al. (2011) Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 21: 18–25.
[23]
Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM (2011) Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 6: e28862.
[24]
Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, et al. (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8: 278–288.
[25]
Spitz MR, Wu X, Wang Y, Wang LE, Shete S, et al. (2001) Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61: 1354–1357.
[26]
Matullo G, Peluso M, Polidoro S, Guarrera S, Munnia A, et al. (2003) Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol Biomarkers Prev 12: 674–677.
[27]
Huang Y, Li L, Yu L (2009) XRCC1 Arg399Gln, Arg194Trp and Arg280His polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis 24: 331–339.
[28]
Liu L, Yuan P, Wu C, Zhang X, Wang F, et al. (2011) Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 73: 110–115.
[29]
Yeh CC, Hsieh LL, Tang R, Chang-Chieh CR, Sung FC (2005) Vegetable/fruit, smoking, glutathione S-transferase polymorphisms and risk for colorectal cancer in Taiwan. World J Gastroenterol 11: 1473–1480.
[30]
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL (2005) Polymorphisms of the XRCC1, XRCC3, & XPD genes, and colorectal cancer risk: a case-control study in Taiwan. BMC Cancer 5: 12.
[31]
Yeh CC, Sung FC, Tang R, Chang-Chieh CR, Hsieh LL (2007) Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomed Sci 14: 183–193.
[32]
Yeh CC, Lai CY, Hsieh LL, Tang R, Wu FY, et al. (2010) Protein carbonyl levels, glutathione S-transferase polymorphisms and risk of colorectal cancer. Carcinogenesis 31: 228–233.
[33]
Martinez-Balibrea E, Abad A, Aranda E, Sastre J, Manzano JL, et al. (2008) Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44: 1229–1237.
[34]
Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, et al. (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25: 1247–1254.
[35]
Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, et al. (2012) X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys 82: 138–144.
[36]
Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ (2007) Adjuvant treatment of colorectal cancer. CA Cancer J Clin 57: 168–185.
[37]
Artac M, Bozcuk H, Pehlivan S, Akcan S, Pehlivan M, et al. (2010) The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. J Cancer Res Clin Oncol 136: 803–809.
[38]
Duldulao MP, Lee W, Nelson RA, Ho J, Le M, et al. (2013) Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer 119: 1106–1112.
[39]
Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, et al. (2011) Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J 11: 214–226.
[40]
Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, et al. (2006) Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin Cancer Res 12: 2101–2108.
[41]
Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. (2001) DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 92: 562–567.
[42]
Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, et al. (2001) Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22: 917–922.
[43]
Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, et al. (2009) Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 101: 998–1004.
[44]
Yamada T, Tanaka N, Yokoi K, Seya T, Kanazawa Y, et al. (2008) Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer. J Nippon Med Sch 75: 23–27.
[45]
Ohrling K, Edler D, Hallstrom M, Ragnhammar P (2008) Expression of thymidylate synthase in liver and lung metastases of colorectal cancer and their matched primary tumours. Anticancer Res 28: 1741–1747.
[46]
Ye F, Liu Z, Tan A, Liao M, Mo Z, et al. (2013) XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. Cancer Chemother Pharmacol 71: 733–740.
